Tirzepatide
Top: Tirzepatide molecular structure Bottom: Structure using peptide three-letter code | |
| Clinical data | |
|---|---|
| Pronunciation | /tɜːrˈzɛpətaɪd/ tur-ZEP-ə-tyde |
| Trade names | Mounjaro, Zepbound |
| Other names | LY3298176 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622044 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Drug class | Antidiabetic, GLP-1 receptor agonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80% |
| Protein binding | Albumin |
| Metabolism | Proteolytic cleavage, β-oxidation of fatty diacid section and amide hydrolysis |
| Elimination half-life | 5 days |
| Excretion | Urine and feces |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.369.612 |
| Chemical and physical data | |
| Formula | C225H348N48O68 |
| Molar mass | 4813.527 g·mol−1 |
| |
| |
Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes (T2D) and for weight loss. Tirzepatide is administered via subcutaneous injections (under the skin). It is sold in several countries under the brand name Mounjaro for T2D treatment. In the United States, it is sold under the brand name Zepbound for weight loss and for the treatment of obstructive sleep apnea.
The most common side effects of tirzepatide include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain. In 2023, tirzepatide was the 110th-most commonly prescribed medication in the United States, with more than 6 million prescriptions.